Mei Bo Pharmaceutical-B (02181.HK): The application for the market registration of CMAB807X Class Shu (Dicuil monoclonal antibody injection) has been approved.

Zhtng Cijng APP news, Meib Yoy-B (02181.HK) announced that recently, the company's pipeline product CMAB807X, a Hu monoclonal antibody injection, has received approval from the National Medical Products Administration of the People's Republic of China for its New Drug Application (NDA). It is used for (i) the treatment of solid tumor bone metastasis patients or multiple myeloma patients, to delay or reduce the risk of bone-related events (pathological fractures, spinal cord compression, bone radiotherapy, or bone surgery) and (ii) the treatment of inoperable or potentially disabling giant cell tumors of bone, including adult and skeletally mature (defined as at least one mature long bone and weight 45kg) adolescent patients.